“We are delighted to see this preclinical data as it shows that our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” said Paul Stoffels, Scientific Director of Johnson & Johnson . “The results give us confidence as we progress in parallel in the development of our vaccines and in high-end manufacturing …”
The company said it plans to start the final phase of testing in September and have 1,045 people participate in the trial.
Johnson & Johnson competes with a number of other companies in the race for a vaccine, and while other companies have been faster in development, Johnson & Johnson’s ability to produce an immune response in one dose could give it an advantage in the deployment of a vaccine.
The company has not announced an expected price for its injection, but said it is ramping up manufacturing to try and deliver more than a billion doses to people around the world.